What is Perspective Therapeutics, Inc.'s (CATX) StockRank?

MoatMap's StockRank for Perspective Therapeutics, Inc. (CATX) is 23/100, with a Sell signal. This is a composite score combining Quality (29), Value (39), and Momentum (46) factor ranks across MoatMap's 20,000+ stock universe.

Does Perspective Therapeutics, Inc. have an economic moat?

Perspective Therapeutics, Inc. (CATX) has a Quality factor score of 29/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Perspective Therapeutics, Inc. a buy, hold, or sell?

MoatMap's current signal for Perspective Therapeutics, Inc. (CATX) is Sell, based on a StockRank of 23/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is Perspective Therapeutics, Inc. in?

Perspective Therapeutics, Inc. (CATX) operates in the Healthcare sector, specifically the Medical Devices industry (United States).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

CATX

SELLREMOVE

Perspective Therapeutics, Inc. · Healthcare · United States · $462M · Avg Vol: $5M/d

StockRank

P/E (TTM)

—

ROE

-35.3%

D/E

0.0x

Dividend %

—

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

Perspective Therapeutics is a clinical-stage radiopharmaceutical company. It is highly speculative, pre-revenue, and lacks the proven business model and high ROIC required by our Terry Smith and Warren Buffett lenses.

COMPANY DESCRIPTION

Perspective Therapeutics, Inc. develops advanced radiopharmaceuticals and medical devices, specializing in targeted alpha-particle therapies for cancer treatment. The company's competitive moat is driven by its proprietary isotope supply chain, particularly Lead-212, and its specialized brachytherapy product line. It operates as a highly specialized pioneer in the rapidly growing radiopharmaceutical oncology sector.

FINANCIAL SUMMARY (USD)

Year	2021	2022	2023	2024	2025	CAGR
Revenue	—	10.8M	0	0	0	—
EPS	—	-0.06	-0.43	-1.23	-1.40	—
Shares	—	114.0M	114.0M	70.7M	74.3M	-34.8%
Debt	—	0.5M	2.6M	4.1M	3.3M	83.8%
Equity	—	61.3M	75.2M	290.7M	207.0M	50.1%
Op CF	—	-7.7M	-36.9M	-18.3M	-82.5M	—
Inv CF	—	-0.3M	24.4M	-218.9M	41.2M	—
Fin CF	—	56,000	0.8M	289.4M	10.3M	—

PRICE (1Y)-18.1%

SMA 50SMA 200

$2.95

RSI (14)

11.0

52W High

$6.16

From 52W High

0.5%

SCORE BREAKDOWN

Quality

ROIC

-43.7%16.3

ROE

-35.3%22.8

GP/Assets

-34.0%2.8

Op. Margin

-37211.8%0.9

FCF/Assets

-22.0%15.0

Piotroski

12.4

Int. Cover

-50.0x6.4

D/E Ratio

0.01x87.1

Current Ratio

8.74x84.2

Value

P/E (TTM)

—N/A

EV/EBITDA

-0.6x63.4

P/FCF

—N/A

P/B

1.0x79.7

P/S

544.4x3.3

Div Yield

—N/A

Momentum

52W High %

48%21.2

RS 6M

-7%71.2

SMA 50/200

1.06x74.3

EPS Rev 4W

+1.8%81.5

EPS Rev 12W

—N/A

EPS Improve

+18%32.4

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$462M

P/E (Forward)

-2.6x

Gross Margin

0.0%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of CATX are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
CATX	Perspective Therapeutics, Inc.(you)	$462M	23	SELL
LAB	Standard BioTools Inc.	$445M	23	SELL
IMR.AX	Imricor Medical Systems, Inc.	$445M	18	STRONG SELL
CLPT	ClearPoint Neuro, Inc.	$367M	17	STRONG SELL
BBNX	Beta Bionics, Inc.	$539M	12	STRONG SELL
RXST	RxSight, Inc.	$231M	23	SELL
LMRI	Lumexa Imaging Holdings, Inc.	$740M	17	STRONG SELL
SGHT	Sight Sciences, Inc.	$275M	18	STRONG SELL
OFIX	Orthofix Medical Inc.	$384M	36	HOLD
AORT	Artivion, Inc.	$1.1B	23	SELL

Peer medians: ROE -22.4% · P/E 25.3x · Gross margin 44.3%

Perspective Therapeutics, Inc. (CATX) — Stock Score Summary

Perspective Therapeutics, Inc. (CATX) has a MoatMap StockRank of 23/100 based on Quality (29/100), Value (39/100), and Momentum (46/100) factor scores. The current signal is SELL. Perspective Therapeutics is a clinical-stage radiopharmaceutical company. It is highly speculative, pre-revenue, and lacks the proven business model and high ROIC required by our Terry Smith and Warren Buffett lenses.

Key Financial Metrics

Price	$2.95
Market Cap	$462M
P/E (Forward)	-2.56
Price/Book	0.97
Return on Equity	-35.3%
Return on Invested Capital	-43.7%
Debt/Equity	1.22
Gross Margin	0.0%
Operating Margin	-37211.8%
Revenue Growth	-77.8%
Free Cash Flow	$-59M

Perspective Therapeutics, Inc. operates in the Medical Devices industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Perspective Therapeutics, Inc.’s (CATX) StockRank?: MoatMap’s StockRank for Perspective Therapeutics, Inc. (CATX) is 23/100, with a Sell signal. It is a composite of Quality (29), Value (39), and Momentum (46) factor ranks across MoatMap’s 20,000+ stock universe.
Does Perspective Therapeutics, Inc. have an economic moat?: Perspective Therapeutics, Inc. (CATX) has a Quality factor score of 29/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Perspective Therapeutics, Inc. a buy, hold, or sell?: MoatMap’s current signal for Perspective Therapeutics, Inc. (CATX) is Sell, based on a StockRank of 23/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Perspective Therapeutics, Inc. in?: Perspective Therapeutics, Inc. (CATX) operates in the Healthcare sector, specifically the Medical Devices industry (United States).